203 related articles for article (PubMed ID: 24449207)
21. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
23. Enzymatic radiosynthesis of a
Lowe PT; Dall'Angelo S; Fleming IN; Piras M; Zanda M; O'Hagan D
Org Biomol Chem; 2019 Feb; 17(6):1480-1486. PubMed ID: 30681115
[TBL] [Abstract][Full Text] [Related]
24. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K
Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532
[TBL] [Abstract][Full Text] [Related]
25. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.
Yao V; Berkman CE; Choi JK; O'Keefe DS; Bacich DJ
Prostate; 2010 Feb; 70(3):305-16. PubMed ID: 19830782
[TBL] [Abstract][Full Text] [Related]
26. The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.
Ben Jemaa A; Sallami S; Ramarli D; Colombatti M; Oueslati R
Inflammation; 2013 Jun; 36(3):643-50. PubMed ID: 23250823
[TBL] [Abstract][Full Text] [Related]
27. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.
Nedrow-Byers JR; Moore AL; Ganguly T; Hopkins MR; Fulton MD; Benny PD; Berkman CE
Prostate; 2013 Mar; 73(4):355-62. PubMed ID: 22911263
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
29. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
[TBL] [Abstract][Full Text] [Related]
31. Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Guo Z; Lai Y; Du T; Zhang Y; Chen J; Bi L; Lin T; Liu H; Wang W; Xu K; Jiang C; Han J; Zhang C; Dong W; Huang J; Huang H
Chin Med J (Engl); 2014; 127(5):929-36. PubMed ID: 24571890
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
33. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
[TBL] [Abstract][Full Text] [Related]
34. Histopathological and immunohistochemical characterization of canine prostate cancer.
Lai CL; van den Ham R; van Leenders G; van der Lugt J; Mol JA; Teske E
Prostate; 2008 Apr; 68(5):477-88. PubMed ID: 18196537
[TBL] [Abstract][Full Text] [Related]
35. A PSMA-targeted doxorubicin small-molecule drug conjugate.
Yoon H; Savoy EA; Mesbahi N; Hendricksen AT; March GL; Fulton MD; Backer BS; Berkman CE
Bioorg Med Chem Lett; 2024 May; 104():129712. PubMed ID: 38521177
[TBL] [Abstract][Full Text] [Related]
36. [Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma].
Ren JQ; Chen ZQ; Zheng L; Chen Q; Li H; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):735-8. PubMed ID: 15733392
[TBL] [Abstract][Full Text] [Related]
37. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
39. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Bernacki KD; Fields KL; Roh MH
Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
